Advertisement
Advertisement
U.S. markets close in 3 hours 11 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
2.2000+0.0600 (+2.80%)
As of 12:48PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close2.1400
Open2.1700
Bid2.1800 x 800
Ask2.1900 x 1200
Day's Range2.1400 - 2.2400
52 Week Range2.0200 - 8.7300
Volume619,487
Avg. Volume984,815
Market Cap191.219M
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-1.4100
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALLK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Allakos Inc.
    Daily – Vickers Top Buyers & Sellers for 03/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Allakos Appoints Neil Graham to its Board of Directors

    SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan P

  • GlobeNewswire

    Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

    SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events Presented preclinical data at the European Academy of Allergy and Clinical Immunology (“EAACI”) Hybrid Congress 2023 highlighting lirentelimab and AK006

  • GlobeNewswire

    Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

    SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and curren

Advertisement
Advertisement